跳转至内容
Merck

SAB1400064

Sigma-Aldrich

Anti-CYP3A4 antibody produced in mouse

IgG fraction of antiserum, buffered aqueous solution

别名:

Anti-CP33, Anti-CP34, Anti-CYP3A, Anti-CYP3A3, Anti-HLP, Anti-MGC126680, Anti-NF-25, Anti-P450C3, Anti-P450PCN1

登录查看公司和协议定价


About This Item

MDL號碼:
分類程式碼代碼:
12352203
NACRES:
NA.41

生物源

mouse

品質等級

共軛

unconjugated

抗體表格

IgG fraction of antiserum

抗體產品種類

primary antibodies

無性繁殖

polyclonal

形狀

buffered aqueous solution

物種活性

human

技術

immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: 1 μg/mL

UniProt登錄號

運輸包裝

dry ice

儲存溫度

−20°C

目標翻譯後修改

unmodified

基因資訊

human ... CYP3A4(1576)

一般說明

Cytochrome P450 3A4 (CYP3A4), the ubiquitous cytochrome P450 (CYP) seen in the adult liver and intestine, belongs to the CYP3A subfamily. The CYP3A4 gene with 13 exons is located on human chromosome 7q22.1.

免疫原

CYP3A4 (AAI01632.1, 1 a.a. ~ 503 a.a) full-length human protein.

Sequence
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA

應用

Anti-CYP3A4 antibody produced in mouse has been used in the immunohistochemical analysis (1:100) and immunofluorescence staining (1:200).

生化/生理作用

Cytochrome P450 3A4 (CYP3A4) plays a key role in the metabolism of several antineoplastic drugs. It aids in the catalysis of a wide range of substrates. CYP3A4 can detoxify bile acids. CYP3A4 gene mutations can disrupt the metabolism of commonly used medications, resulting in harmful blood concentrations of drugs. Such CYP3A4 polymorphisms may also affect the detoxification of bile acid.

外觀

Solution in phosphate buffered saline, pH 7.4

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.

儲存類別代碼

10 - Combustible liquids

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Human Pluripotent Stem Cell-Derived Organoids as a Model of Intestinal Xenobiotic Metabolism
Sasaki K, et al.
Stem cell investigation, 1-10 (2021)
Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters
Lazar A, et al.
Handbook of Analytical Separations , 5, 321-354 (2004)
Hideaki Nitta et al.
Journal of clinical medicine, 13(13) (2024-07-13)
Background: Aggressive mature T-cell lymphoma (TCL) is a disease that carries a poor prognosis. Methods: We analyzed the expression of 22 tumor cell functional proteins in 16 randomly selected patients with TCL. Immunohistochemistry was performed in paraffin-embedded tumor tissue sections
Jiezhong Chen et al.
Annals of translational medicine, 2(1), 7-7 (2014-10-22)
CYP3A4 is a major cytochrome P450. It catalyses a broad range of substrates including xenobiotics such as clinically used drugs and endogenous compounds bile acids. Its function to detoxify bile acids could be used for treating cholestasis, which is a
Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro
Han M, et al.
Chemico-Biological Interactions, 109559-109559 (2021)

商品

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

Phase I biotransformation reactions increase drug compound polarity, mainly occurring in hepatic circulation.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门